RU2012119488A - Конденсированные азиновые производные для лечения заболеваний, связанных с ацетилхолиновым рецептором - Google Patents
Конденсированные азиновые производные для лечения заболеваний, связанных с ацетилхолиновым рецептором Download PDFInfo
- Publication number
- RU2012119488A RU2012119488A RU2012119488/04A RU2012119488A RU2012119488A RU 2012119488 A RU2012119488 A RU 2012119488A RU 2012119488/04 A RU2012119488/04 A RU 2012119488/04A RU 2012119488 A RU2012119488 A RU 2012119488A RU 2012119488 A RU2012119488 A RU 2012119488A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- cycloalkyl
- heterocyclic derivative
- optionally substituted
- group
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 25
- 229910052736 halogen Inorganic materials 0.000 claims abstract 11
- 150000002367 halogens Chemical class 0.000 claims abstract 11
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 8
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 8
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 8
- 125000001424 substituent group Chemical group 0.000 claims abstract 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 6
- 125000005842 heteroatom Chemical group 0.000 claims abstract 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims abstract 3
- 125000005843 halogen group Chemical group 0.000 claims abstract 3
- 239000012634 fragment Substances 0.000 claims abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- -1 1,4-diazabicyclo [3.2.2] non-4-yl Chemical group 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003367 polycyclic group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 0 *C(N(*)*=C1C(*)=CC=CC=C/C=C1)=* Chemical compound *C(N(*)*=C1C(*)=CC=CC=C/C=C1)=* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25110109P | 2009-10-13 | 2009-10-13 | |
| EP09172872.5 | 2009-10-13 | ||
| US61/251,101 | 2009-10-13 | ||
| EP09172872 | 2009-10-13 | ||
| PCT/EP2010/065160 WO2011045258A1 (en) | 2009-10-13 | 2010-10-11 | Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012119488A true RU2012119488A (ru) | 2013-11-20 |
Family
ID=42040651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012119488/04A RU2012119488A (ru) | 2009-10-13 | 2010-10-11 | Конденсированные азиновые производные для лечения заболеваний, связанных с ацетилхолиновым рецептором |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8841289B2 (enExample) |
| EP (1) | EP2488520B1 (enExample) |
| JP (1) | JP2013507417A (enExample) |
| KR (1) | KR20120100913A (enExample) |
| CN (1) | CN102666540A (enExample) |
| AU (1) | AU2010305825A1 (enExample) |
| BR (1) | BR112012008518A2 (enExample) |
| CA (1) | CA2776835A1 (enExample) |
| IN (1) | IN2012DN02968A (enExample) |
| MX (1) | MX2012004289A (enExample) |
| RU (1) | RU2012119488A (enExample) |
| WO (1) | WO2011045258A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014001265A2 (pt) | 2011-07-29 | 2017-02-21 | Taisho Pharmaceutical Co Ltd | composto de amidina ou seu sal |
| RU2696572C2 (ru) | 2012-03-07 | 2019-08-05 | Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) | 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение |
| CA2874193A1 (en) * | 2012-05-22 | 2013-11-28 | Vladimir BAJIC | Combination comprising parthenolide for use in the treatment of alzheimer's disease and other neurodegenerative disorders |
| CA2922469A1 (en) | 2013-09-11 | 2015-03-19 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| WO2016034703A1 (en) | 2014-09-05 | 2016-03-10 | AbbVie Deutschland GmbH & Co. KG | Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases |
| CA2971413A1 (en) | 2014-12-16 | 2016-06-23 | Axovant Sciences Gmbh | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
| MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
| TWI698436B (zh) | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶 |
| EP3253765A1 (en) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors |
| EP3253738A1 (en) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
| HK1248221A1 (zh) | 2015-02-05 | 2018-10-12 | Forma Therapeutics, Inc. | 异噻唑啉酮类，吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂 |
| CN106146410B (zh) * | 2015-04-03 | 2018-10-12 | 中南大学 | 6-氨基-4(3h)-喹唑啉酮衍生物及其合成方法和用途 |
| CN106279211B (zh) | 2015-06-03 | 2020-09-15 | 北京大学 | 一种噻唑并嘧啶酮化合物及其制备方法和应用 |
| CN107847494A (zh) | 2015-06-10 | 2018-03-27 | 阿考温特科学股份有限公司 | 作为α7‑烟碱乙酰胆碱受体激动剂的氨基苯并异噁唑化合物 |
| US10428062B2 (en) | 2015-08-12 | 2019-10-01 | Axovant Sciences Gmbh | Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors |
| ES2821010T3 (es) * | 2015-12-09 | 2021-04-23 | Cadent Therapeutics Inc | Moduladores heteroaromáticos del receptor NMDA y usos de los mismos |
| WO2017100599A1 (en) | 2015-12-09 | 2017-06-15 | Luc Therapeutics | Thienopyrimidinone nmda receptor modulators and uses thereof |
| AU2017382339B2 (en) | 2016-12-22 | 2024-02-15 | Novartis Ag | NMDA receptor modulators and uses thereof |
| WO2020004594A1 (ja) * | 2018-06-27 | 2020-01-02 | 株式会社リボルナバイオサイエンス | 脊髄性筋萎縮症の予防または治療剤 |
| HU231414B1 (hu) * | 2018-07-13 | 2023-08-28 | Richter Gedeon Nyrt. | Tiadiazin származékok |
| CA3102326A1 (en) | 2018-07-26 | 2020-01-30 | Domain Therapeutics | Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4 |
| PT3830092T (pt) | 2018-08-03 | 2023-07-25 | Novartis Ag | Moduladores do recetor nmda heteroaromáticos e suas utilizações |
| WO2021198191A1 (en) | 2020-03-30 | 2021-10-07 | Enyo Pharma | Quinazolinone derivatives and uses thereof for treating a cancer |
| EP4126847A1 (en) | 2020-03-30 | 2023-02-08 | ENYO Pharma | Quinazolinone derivatives and uses thereof for treating a cancer |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| CN112898290B (zh) * | 2021-01-29 | 2022-08-05 | 中南大学 | 异噁唑甲酰胺基-4(3h)-喹唑啉酮衍生物及其合成方法和用途 |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| TW202539670A (zh) * | 2024-02-23 | 2025-10-16 | 大陸商海思科醫藥集團股份有限公司 | Braf抑制劑的製備方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0000540D0 (sv) | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
| CA2444598A1 (en) * | 2001-04-20 | 2003-10-31 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of gsk-3 |
| EP1472248A1 (en) | 2002-01-17 | 2004-11-03 | Eli Lilly And Company | Modulators of acetylcholine receptors |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| TW200536830A (en) * | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
| PT1910333E (pt) * | 2005-07-26 | 2013-08-01 | Sanofi Sa | Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase |
| NZ575426A (en) | 2006-09-11 | 2010-09-30 | Organon Nv | Quinazolinone and isoquinolinone acetamide derivatives useful for the treatment of disorders which are influenced by modulation of the activity of the hpa axis |
| ATE502027T1 (de) * | 2006-12-27 | 2011-04-15 | Sanofi Aventis | Substituierte isochinoline und ihre verwendung als rho-kinase-inhibitoren |
| JP2010229035A (ja) * | 2007-08-01 | 2010-10-14 | Taisho Pharmaceutical Co Ltd | ピリドピリミジン−４−オン誘導体 |
| CA2705752A1 (en) * | 2007-11-14 | 2009-05-22 | Neurosearch A/S | Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use |
| EP2249455A1 (en) | 2008-02-29 | 2010-11-10 | Techno Core International Co., Ltd. | Charging device and quality judging device of pack cell |
-
2010
- 2010-10-11 CN CN2010800465507A patent/CN102666540A/zh active Pending
- 2010-10-11 WO PCT/EP2010/065160 patent/WO2011045258A1/en not_active Ceased
- 2010-10-11 AU AU2010305825A patent/AU2010305825A1/en not_active Abandoned
- 2010-10-11 JP JP2012533593A patent/JP2013507417A/ja active Pending
- 2010-10-11 US US13/501,587 patent/US8841289B2/en active Active
- 2010-10-11 RU RU2012119488/04A patent/RU2012119488A/ru unknown
- 2010-10-11 BR BR112012008518A patent/BR112012008518A2/pt not_active Application Discontinuation
- 2010-10-11 KR KR1020127009340A patent/KR20120100913A/ko not_active Withdrawn
- 2010-10-11 CA CA2776835A patent/CA2776835A1/en not_active Abandoned
- 2010-10-11 IN IN2968DEN2012 patent/IN2012DN02968A/en unknown
- 2010-10-11 EP EP10771062.6A patent/EP2488520B1/en active Active
- 2010-10-11 MX MX2012004289A patent/MX2012004289A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013507417A (ja) | 2013-03-04 |
| CA2776835A1 (en) | 2011-04-21 |
| IN2012DN02968A (enExample) | 2015-07-31 |
| KR20120100913A (ko) | 2012-09-12 |
| CN102666540A (zh) | 2012-09-12 |
| US8841289B2 (en) | 2014-09-23 |
| BR112012008518A2 (pt) | 2016-04-05 |
| AU2010305825A1 (en) | 2012-04-19 |
| MX2012004289A (es) | 2012-06-12 |
| US20120208796A1 (en) | 2012-08-16 |
| WO2011045258A1 (en) | 2011-04-21 |
| EP2488520A1 (en) | 2012-08-22 |
| EP2488520B1 (en) | 2015-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102594476B1 (ko) | C-kit 억제제로서의 아미노티아졸 화합물 | |
| AU2010297921B2 (en) | Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof | |
| CN112442050A (zh) | 一种ret抑制剂、其药物组合物及其用途 | |
| ES2928169T3 (es) | Derivados de 4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amina como inhibidores de proteína cinasa, y método de preparación y uso médico de los mismos | |
| BR112019012957A2 (pt) | derivados de tetra-hidroimidazo[4,5-c]piridina como indutores de internalização de pd-l1 | |
| CN104725359B (zh) | 取代的哌嗪化合物及其使用方法和用途 | |
| WO2019165073A1 (en) | Shp2 phosphatase inhibitors and methods of use thereof | |
| AU2014221799A1 (en) | Novel pyrazole derivative | |
| BR102014017997B1 (pt) | compostos do tipo fosfato, processo para sua preparação, composições farmacêuticas contendo os mesmos, seus usos e associações | |
| RU2012148246A (ru) | 5, 7- замещенные-имидазо[1, 2-с]пиримидины как ингибиторы jak-киназ | |
| ES3062921T3 (en) | Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method | |
| JP2009507032A (ja) | 新規なイミダゾ系複素環 | |
| WO2019241292A1 (en) | Hepatitis b capsid assembly modulators | |
| AR049300A1 (es) | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos | |
| JP2016523270A5 (enExample) | ||
| JP2023537055A (ja) | Ａｔｒ阻害剤およびその使用 | |
| RU2008125040A (ru) | ПРОИЗВОДНЫЕ АРИЛ-ИЗОКСАЗОЛ-4-ИЛ-ИМИДАЗО[1.5-a]ПИРИДИНА | |
| JP2018522909A (ja) | ヒト免疫不全ウイルス複製の阻害剤としての５−（ｎ−縮合三環式アリールテトラヒドロイソキノリン−６−イル）ピリジン−３−イル酢酸誘導体 | |
| AU2017265383B2 (en) | Treatment of neurological disorders | |
| RU2015102095A (ru) | 3-о-гетероарилингенол | |
| AU2015316719A1 (en) | Imidazo[2,1-b]thiazole and 5,6-dihydroimidazo[2,1-b]thiazole derivatives useful as S100-inhibitors | |
| AR052019A1 (es) | COMPUESTOS HETEROCICLICOS, PROCESOS DE PREPARACIoN Y MÉTODO PARA TRATAR ENFERMEDADES HIPERPROLIFERATIVAS | |
| EA201792087A1 (ru) | ПРОИЗВОДНЫЕ 7-(МОРФОЛИН-4-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИМИДИНА, ПРИГОДНЫЕ ДЛЯ ЛЕЧЕНИЯ ИММУННЫХ ИЛИ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ИЛИ РАКА | |
| JP2018522913A (ja) | ヒト免疫不全ウイルス複製の阻害剤としての５−（ｎ−［６，５］−縮合二環式アリールテトラヒドロイソキノリン−６−イル）ピリジン−３−イル酢酸誘導体 | |
| ES2628818T3 (es) | Compuestos triazólicos tricíclicos como ligandos de receptores sigma |